Patrick Schöffski
Impact in
- Gastroenterology top 0.02%
- Gastrointestinal Tumor Research and Treatment
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- Vascular Tumors and Angiosarcomas
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
Papers in
- Gastroenterology 106
- Gastrointestinal Tumor Research and Treatment 106
-
- Sarcoma Diagnosis and Treatment 104
- Renal cell carcinoma treatment 33
- Gastric Cancer Management and Outcomes 31
- Co-authors
- Jean‐Yves Blay (51 shared papers)Maria Dêbiec‐Rychter (59 shared papers)Agnieszka Woźniak (76 shared papers)Raf Sciot (69 shared papers)Herlinde Dumez (45 shared papers)Jaap Verweij (23 shared papers)Pascal Wolter (31 shared papers)Axel Le Cesne (21 shared papers)
- Journals
- Annals of Oncology (56 papers)European Journal of Cancer (48 papers)Clinical Cancer Research (25 papers)Journal of Clinical Oncology (24 papers)British Journal of Cancer (21 papers)
- Partner nations
- BelgiumUnited StatesGermany
In The Last Decade
Patrick Schöffski
422 papers receiving 32.8k citations
Patrick Schöffski's Hit Papers
Peers
Comparison fields: 5 of 161
- Gastroenterology 5.0k
- Oncology 12.7k
- Pulmonary and Respiratory Medicine 13.3k
- Cancer Research 2.6k
- Pathology and Forensic Medicine 2.4k
Countries citing papers authored by Patrick Schöffski
This map shows the geographic impact of Patrick Schöffski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Schöffski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Schöffski more than expected).
Fields of papers citing papers by Patrick Schöffski
This network shows the impact of papers produced by Patrick Schöffski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Schöffski. The network helps show where Patrick Schöffski may publish in the future.
Co-authors
The 25 scholars most cited alongside Patrick Schöffski, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 435 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma Hit paper breakdown → | 2019 | 2848 |
| 2 | Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial Hit paper breakdown → | 2012 | 1703 |
| 3 | Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial Hit paper breakdown → | 2012 | 1129 |
| 4 | Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2018 | 1096 |
| 5 | Cabozantinib in Progressive Medullary Thyroid Cancer Hit paper breakdown → | 2013 | 967 |
| 6 | Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial Hit paper breakdown → | 2014 | 928 |
| 7 | Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ Hit paper breakdown → | 2021 | 690 |
| 8 | 2004 | 658 | |
| 9 | Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial Hit paper breakdown → | 2016 | 623 |
| 10 | Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2018 | 598 |
| 11 | Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043) Hit paper breakdown → | 2009 | 588 |
| 12 | Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial Hit paper breakdown → | 2009 | 498 |
| 13 | Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma Hit paper breakdown → | 2022 | 492 |
| 14 | Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial Hit paper breakdown → | 2017 | 485 |
| 15 | 2001 | 453 | |
| 16 | 2004 | 450 | |
| 17 | Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2018 | 436 |
| 18 | 2002 | 392 | |
| 19 | Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial Hit paper breakdown → | 2012 | 378 |
| 20 | Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2021 | 371 |
About Patrick Schöffski
Patrick Schöffski is a scholar working on Gastroenterology, Pulmonary and Respiratory Medicine, Oncology, Hematology and Pathology and Forensic Medicine, having authored 435 papers that have together received 33.6k indexed citations. Recurring topics across this work include Gastrointestinal Tumor Research and Treatment (106 papers), Sarcoma Diagnosis and Treatment (104 papers), Renal cell carcinoma treatment (33 papers), Gastric Cancer Management and Outcomes (31 papers), Colorectal Cancer Treatments and Studies (28 papers), Vascular Tumors and Angiosarcomas (24 papers), Gastrointestinal disorders and treatments (15 papers) and Cardiac tumors and thrombi (14 papers). The work is most often cited by research in Gastroenterology (5.0k citations), Oncology (12.7k citations), Pulmonary and Respiratory Medicine (13.3k citations), Cancer Research (2.6k citations) and Pathology and Forensic Medicine (2.4k citations). Patrick Schöffski has collaborated with scholars based in Belgium, United States and Germany. Frequent co-authors include Jean‐Yves Blay, Maria Dêbiec‐Rychter, Agnieszka Woźniak, Raf Sciot, Herlinde Dumez, Jaap Verweij, Pascal Wolter, Axel Le Cesne, Hans Gelderblom and Sandrine I. Marreaud. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Clinical Cancer Research, Journal of Clinical Oncology and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.